×
You can find our latest news below
All Hytest SARS-CoV-2 nucleoprotein (NP) antibodies (Cat. #3CV4), including monoclonal antibodies (MAbs) C706, C524, C518, C715, and C527, target the N-terminal part of the nucleoprotein, specifically the region N47-A173.
We are proud to sponsor the EFLM Cardiac Marker Award, which recognizes remarkable scientific work in the field of cardiovascular diseases. This award, presented by the European Federation of Laboratory Medicine (EFLM), honors the best original research paper on cardiac marker measurements and cardiovascular risk assessment.
Hytest is a Leading Raw Material Supplier for the IVD Industry over the past 30 years
We are in the process of developing our North American operations to align with the same standards we use in Hytest Finland.
As we celebrate our 30th anniversary, Hytest is proud to offer a special opportunity to our valued customers.
Celebrating Excellence in Cardiovascular Diagnostics: Hytest Sponsors IFCC Distinguished Award
May is Cancer Survivor Month. We honor the strength, resilience, and courage of cancer survivors around the world.
We are excited to announce the launch of a new recombinant Glial Fibrillary Acidic Protein (GFAP) antigen, Cat# 8G47.
Hytest is pleased to announce the addition of recombinant monoclonal antibodies RC3A6 and RC8E2 (Cat. # 2I1) to our Insulin product portfolio.
Our
monoclonal antibodies (MAbs) can recognize up to 16 different strains of the
influenza A virus.
Meet HyTest team at the
China Association of Clinical
Laboratory Practice Expo!
Launch of HyTest’s latest monoclonal antibodies targeting the nucleoprotein of influenza B virus!
The Brain Injury Association of America (BIAA) designates March as a month to raise awareness about brain injuries.
We are pleased to inform you that Hytest North America, a subsidiary of Hytest Ltd, will launch local operations in March 2024!
February is American Heart Month, emphasizing the importance of heart health, with a focus on women this year due to their unique risk and often underdiagnosed heart conditions. Current AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guidelines for the Evaluation and Diagnosis of Acute Chest Pain highlight the gender-specific nature of heart disease diagnosis, particularly noting that women generally have lower baseline levels of troponin.
At HyTest, we are dedicated to meeting this gender-specific diagnostic need through our innovations in cardiac diagnostics, especially in troponins. Our product range includes approximately 50 antibodies targeting various epitopes of the cardiac troponin I (cTnI) molecule, complemented by our advanced cardiac troponin and troponin complex antigens. For more detailed information, please refer to our Cardiac Markers Brochure.
HyTest antibodies should recognize Pirola and Eris variants.
Copyright © Hytest Ltd.